Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Cited by (12,156)

Items 201–300 of 12,156

1. Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019
   Dalton Bertolim Précoma, Gláucia Maria Moraes de Oliveira, Antônio Felipe Leite Simão, Óscar Pereira Dutra, Otávio Rizzi Coelho-Filho, Maria Cristina de Oliveira Izar, Rui Póvoa, Isabela de Carlos Back Giuliano, Aristóteles Comte de Alencar Filho, Carlos Alberto Machado et al. · 2019 · Arquivos Brasileiros de Cardiologia
2. Pathophysiology of heart failure
   Robert H. G. Schwinger · 2021 · Cardiovascular Diagnosis and Therapy
3. 10. Cardiovascular Disease and Risk Management: <i>Standards of Care in Diabetes—2024</i>
   American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., Aleppo, Grazia, Bannuru, Raveendhara R., Bruemmer, Dennis, Collins, Billy S., Das, Sandeep R., Ekhlaspour, Laya, Hilliard, Marisa E., Johnson, Eric L. et al. · 2024 · Diabetes Care
4. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018
   John James Atherton, Andrew Paul Sindone, Carmine G. De Pasquale, Andrea L Driscoll, Peter Simon Macdonald, Ingrid Hopper, Peter M. Kistler, Tom G. Briffa, James Wong, Walter P. Abhayaratna et al. · 2018 · Heart Lung and Circulation
5. Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease
   Guanghong Jia, James R. Sowers · 2021 · Hypertension
6. NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
   Harrison, Stephen A, Rinella, Mary E, Abdelmalek, Manal F, Trotter, James F, Paredes, Angelo H, Arnold, Hays L, Kugelmas, Marcelo, Bashir, Mustafa R, Jaros, Mark J, Ling, Lei et al. · 2018 · The Lancet
7. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study
   Hallberg, Sarah J., McKenzie, Amy L., Williams, Paul T., Bhanpuri, Nasir H., Peters, Anne L., Campbell, Wayne W., Hazbun, Tamara L., Volk, Brittanie M., McCarter, James P., Phinney, Stephen D. et al. · 2018 · Diabetes Therapy
8. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial
   Nassif, Michael E., Windsor, Sheryl L., Tang, Fengming, Khariton, Yevgeniy, Husain, Mansoor, Inzucchi, Silvio E., McGuire, Darren K., Pitt, Bertram, Scirica, Benjamin M., Austin, Bethany et al. · 2019 · Circulation
9. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes
   Suetonia C. Palmer, Dimitris Mavridis, Antonio Nicolucci, David Wayne Johnson, Marcello A. Tonelli, Jonathan C. Craig, Jasjot K. Maggo, Vanessa Gray, Giorgia De Berardis, Marinella Ruospo et al. · 2016 · JAMA
10. Diabetes Dyslipidemia
    Jonathan D. Schofield, Yifen Liu, Prasanna Rao‐Balakrishna, Rayaz Ahmed Malik, Handrean Soran · 2016 · Diabetes Therapy
11. Reducing the Global Burden of Cardiovascular Disease, Part 2
    Darryl P. Leong, Philip G. Joseph, Martin McKee, Sonia Savitri Anand, Koon Kang Teo, Jon-David Schwalm, Salim Yusuf · 2017 · Circulation Research
12. Insulin Signaling and Heart Failure
    Christian Riehle, E. Dale Abel · 2016 · Circulation Research
13. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
    2017 · New England Journal of Medicine
14. Targeting innate immune mediators in type 1 and type 2 diabetes
    Donath, Marc Y., Dinarello, Charles A., Mandrup-Poulsen, Thomas · 2019 · Nature Reviews Immunology
15. Empagliflozin in Heart Failure
    Matthew Dallas Griffin, Veena S. Rao, Juan Betuel Ivey-Miranda, James H. Fleming, Devin Mahoney, Christopher Maulion, Nisha Suda, Krishmita Siwakoti, Tariq Ahmad, Daniel Louis Jacoby et al. · 2020 · Circulation
16. Vascular Complications of Diabetes
    Joshua A. Beckman, Mark A. Creager · 2016 · Circulation Research
17. Targeting Mitochondria-Inflammation Circuit by β-Hydroxybutyrate Mitigates HFpEF
    Yan Deng, Maodi Xie, Qian Li, Xuewen Xu, Wei Ou, Yabing Zhang, Haitao Xiao, Hai Yu, Yanyi Zheng, Yu Liang et al. · 2020 · Circulation Research
18. Type-2 diabetes mellitus and cardiovascular disease
    Henning, Robert J · 2018 · Future Cardiology
19. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
    Griffin, Simon J., Leaver, James K., Irving, Greg J. · 2017 · Diabetologia
20. 10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetes—2021</i>
    American Diabetes Association · 2021 · Diabetes Care
21. Management of Hypertension in Chronic Kidney Disease
    Dan Pugh, Peter James Gallacher, Neeraj Dhaun · 2019 · Drugs
22. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes
    Sean Lee Zheng, Alistair Roddick, Rochan Agha-Jaffar, Matthew James Shun-Shin, Dárrel P. Francis, Nick S. Oliver, Karim M. Meeran · 2018 · JAMA
23. Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association
    Rodica Pop‐Busui, James L. Januzzi, Dennis Bruemmer, Sonia Butalia, Jennifer B. Green, William B. Horton, Colette M. Knight, Moshe Levi, Neda Rasouli, Caroline Regina Richardson · 2022 · Diabetes Care
24. Atrial Fibrillation and Diabetes Mellitus
    Allen Wang, Jennifer B. Green, Jonathan L. Halperin, Jonathan Paul Piccini · 2019 · Journal of the American College of Cardiology
25. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
    Juan P. Frías, Cristian Guja, Elise Hardy, Azazuddin Ahmed, Fang Dong, Peter Öhman, Serge A Jabbour · 2016 · The Lancet Diabetes & Endocrinology
26. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
    American Diabetes Association · 2018 · Diabetes Care
27. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
    Tahrani, Abd A., Barnett, Anthony H., Bailey, Clifford J. · 2016 · Nature Reviews Endocrinology
28. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
    Heerspink, Hiddo J L, Greene, Tom, Tighiouart, Hocine, Gansevoort, Ron T, Coresh, Josef, Simon, Andrew L, Chan, Tak Mao, Hou, Fan Fan, Lewis, Julia B, Locatelli, Francesco et al. · 2019 · The Lancet Diabetes &amp; Endocrinology
29. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
    Eriksson, Jan W., Lundkvist, Per, Jansson, Per-Anders, Johansson, Lars, Kvarnström, Mats, Moris, Linda, Miliotis, Tasso, Forsberg, Gun-Britt, Risérus, Ulf, Lind, Lars et al. · 2018 · Diabetologia
30. 2020 Clinical practice guidelines for Chronic heart failure
    Russian Society of Cardiology · 2020 · Russian Journal of Cardiology
31. 11. Microvascular Complications and Foot Care: <i>Standards of Medical Care in Diabetes—2021</i>
    American Diabetes Association · 2021 · Diabetes Care
32. Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote glucose disposal and inflammation
    Erez Dror, Élise Dalmas, Daniel T. Meier, Stephan Wueest, Julien Thévenet, Constanze Thienel, Katharina Timper, Thierry M. Nordmann, Shuyang Traub, Friederike Schulze et al. · 2017 · Nature Immunology
33. From Systemic Inflammation to Myocardial Fibrosis
    Walter J. Paulus, Michael R. Zile · 2021 · Circulation Research
34. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
    Heerspink, Hiddo J.L., Kosiborod, Mikhail, Inzucchi, Silvio E., Cherney, David Z.I. · 2018 · Kidney International
35. Empagliflozin Increases Cardiac Energy Production in Diabetes
    Subodh Verma, Sonia Rawat, Kim L. Ho, Cory S. Wagg, Liyan Zhang, Hwee Teoh, John E. Dyck, Golam Mezbah Uddin, Gavin Y. Oudit, Eric Mayoux et al. · 2018 · JACC Basic to Translational Science
36. The cardio-renal-metabolic connection: a review of the evidence
    Marassi, Marella, Fadini, Gian Paolo · 2023 · Cardiovascular Diabetology
37. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG outcome randomised, placebo-controlled trial
    Cherney, David Z I, Zinman, Bernard, Inzucchi, Silvio E, Koitka-Weber, Audrey, Mattheus, Michaela, von Eynatten, Maximilian, Wanner, Christoph · 2017 · The Lancet Diabetes &amp; Endocrinology
38. 13. Older Adults: <i>Standards of Medical Care in Diabetes—2022</i>
    American Diabetes Association Professional Practice Committee · 2022 · Diabetes Care
39. SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition
    Tomita, Issei, Kume, Shinji, Sugahara, Sho, Osawa, Norihisa, Yamahara, Kosuke, Yasuda-Yamahara, Mako, Takeda, Naoko, Chin-Kanasaki, Masami, Kaneko, Tatsuroh, Mayoux, Eric et al. · 2020 · Cell Metabolism
40. The effect of dapagliflozin treatment on epicardial adipose tissue volume
    Takao Sato, Yoshifusa Aizawa, Sho Yuasa, Shohei Kishi, Koichi Fuse, Satoshi Fujita, Yoshio Ikeda, Hitoshi Kitazawa, Minoru Takahashi, Masahito Sato et al. · 2018 · Cardiovascular Diabetology
41. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
    Zinman, Bernard, Bhosekar, Vaishali, Busch, Robert, Holst, Ingrid, Ludvik, Bernhard, Thielke, Desirée, Thrasher, James, Woo, Vincent, Philis-Tsimikas, Athena · 2019 · The Lancet Diabetes &amp; Endocrinology
42. Targeting hepatic glucose metabolism in the treatment of type 2 diabetes
    Amy K. Rines, Kfir Sharabi, Clint D.J. Tavares, Pere Puigserver · 2016 · Nature Reviews Drug Discovery
43. The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor
    Rossella D’Oria, Rossella Schipani, Anna Leonardini, Annalisa Natalicchio, Sebastio Perrini, Angelo Cignarelli, Luigi Laviola, Francesco Giorgino · 2020 · Oxidative Medicine and Cellular Longevity
44. 11. Microvascular Complications and Foot Care: <i>Standards of Medical Care in Diabetes−2020</i>
    American Diabetes Association · 2020 · Diabetes Care
45. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors
    Danne, Thomas, Garg, Satish, Peters, Anne L., Buse, John B., Mathieu, Chantal, Pettus, Jeremy H., Alexander, Charles M., Battelino, Tadej, Ampudia-Blasco, F. Javier, Bode, Bruce W. et al. · 2019 · Diabetes Care
46. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
    Anna Solini, Livia Giannini, Marta Seghieri, Edoardo Vitolo, Stefano Taddei, Lorenzo Ghiadoni, Rosa María Bruno · 2017 · Cardiovascular Diabetology
47. Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease
    Mazer, C. David, Hare, Gregory M.T., Connelly, Philip W., Gilbert, Richard E., Shehata, Nadine, Quan, Adrian, Teoh, Hwee, Leiter, Lawrence A., Zinman, Bernard, Jüni, Peter et al. · 2020 · Circulation
48. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm—2023 update
    Samson, Susan L., Vellanki, Priyathama, Blonde, Lawrence, Christofides, Elena A., Galindo, Rodolfo J., Hirsch, Irl B., Isaacs, Scott D., Izuora, Kenneth E., Low Wang, Cecilia C., Twining, Christine L. et al. · 2023 · Endocrine Practice
49. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor
    Yumei Ye, Mandeep Bajaj, Hsiu‐Chiung Yang, Jose R. Perez-Polo, Yochai Birnbaum · 2017 · Cardiovascular Drugs and Therapy
50. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
    Peter Ueda, Henrik Svanström, Mads Melbye, Björn Eliasson, Ann‐Marie Svensson, Stefan Franzén, Soffia Guðbjörnsdóttir, Kristian Hveem, Christian Jonasson, Björn Pasternak · 2018 · BMJ
51. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
    Vincenzo Quagliariello, Michelino De Laurentiis, Domenica Rea, Antônio Barbieri, Maria Gaia Monti, Andreina Carbone, Andrea Paccone, Lucia Altucci, Mariarosaria Conte, Maria Laura Canale et al. · 2021 · Cardiovascular Diabetology
52. Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy
    Marwick, Thomas H., Ritchie, Rebecca, Shaw, Jonathan E., Kaye, David · 2018 · Journal of the American College of Cardiology
53. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum
    William T. Cefalu, Sanjay Kaul, Hertzel C. Gerstein, Rury R. Holman, Bernard Zinman, Jay S. Skyler, Jennifer B. Green, John B. Buse, Silvio E. Inzucchi, Lawrence A. Leiter et al. · 2017 · Diabetes Care
54. Proximal Tubulopathy: Prime Mover and Key Therapeutic Target in Diabetic Kidney Disease
    Richard E. Gilbert · 2017 · Diabetes
55. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
    Kåre I. Birkeland, Marit E. Jørgensen, Bendix Carstensen, Frederik Persson, Hanne Løvdal Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W. Eriksson et al. · 2017 · The Lancet Diabetes & Endocrinology
56. Canagliflozin slows progression of renal function decline independently of glycemic effects
    Heerspink, Hiddo J. L., Desai, Mehul, Jardine, Meg, Balis, Dainius, Meininger, Gary, Perkovic, Vlado · 2017 · Journal of the American Society of Nephrology
57. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
    Rosenstock, Julio, Marquard, Jan, Laffel, Lori M., Neubacher, Dietmar, Kaspers, Stefan, Cherney, David Z., Zinman, Bernard, Skyler, Jay S., George, Jyothis, Soleymanlou, Nima et al. · 2018 · Diabetes Care
58. Ketone bodies: from enemy to friend and guardian angel
    Hubert Kolb, Kerstin Kempf, Martin Röhling, Martina Lenzen-Schulte, Nanette Cathrin Schloot, Stéphan Martin · 2021 · BMC Medicine
59. Diabetic cardiomyopathy - A comprehensive updated review
    Ghulam Murtaza, Hafeez Ul Hassan Virk, Muhammad Faisal Khalid, Carl J. Lavie, Héctor O. Ventura, Debabrata Mukherjee, Vijay K. Ramu, Sukhdeep Singh Bhogal, Gautam Kumar, Madhan Shanmugasundaram et al. · 2019 · Progress in Cardiovascular Diseases
60. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis
    Handelsman, Yehuda, Henry, Robert R., Bloomgarden, Zachary T., Dagogo-Jack, Sam, DeFronzo, Ralph A., Einhorn, Daniel, Ferrannini, Ele, Fonseca, Vivian A., Garber, Alan J., Grunberger, George et al. · 2016 · Endocrine Practice
61. Association of bariatric surgery vs medical obesity treatment with long-term medical complications and obesity-related comorbidities
    Jakobsen, Gunn Signe, Småstuen, Milada Cvancarova, Sandbu, Rune, Nordstrand, Njord, Hofsø, Dag, Lindberg, Morten, Hertel, Jens Kristoffer, Hjelmesæth, Jøran · 2018 · JAMA
62. The Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease
    John R. Ussher, Sammy Elmariah, Robert Edgardo Gerszten, Jason R.B. Dyck · 2016 · Journal of the American College of Cardiology
63. SGLT2 Inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis
    Goldenberg, Ronald M., Berard, Lori D., Cheng, Alice Y.Y., Gilbert, Jeremy D., Verma, Subodh, Woo, Vincent C., Yale, Jean-François · 2016 · Clinical Therapeutics
64. Lipid Use and Misuse by the Heart
    Paul Christian Schulze, Konstantinos Drosatos, Ira J. Goldberg · 2016 · Circulation Research
65. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
    Jelena P. Seferović, Brian Lee Claggett, Sara Bretschger Seidelmann, Ellen W. Seely, Milton Packer, Michael R. Zile, Jean Lucien Rouleau, Karl B Swedberg, Martin P. Lefkowitz, Victor Chengwei Shi et al. · 2017 · The Lancet Diabetes & Endocrinology
66. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
    DAVID H. FITCHETT, Silvio E. Inzucchi, Christopher Paul Cannon, Darren K. McGuire, Benjamin M. Scirica, Odd Erik Johansen, Steven Sambevski, Stefan Kaspers, Egon Pfarr, Jyothis Thomas George et al. · 2019 · Circulation
67. Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US
    Eberly, Lauren A., Yang, Lin, Eneanya, Nwamaka D., Essien, Utibe, Julien, Howard, Nathan, Ashwin S., Khatana, Sameed Ahmed M., Dayoub, Elias J., Fanaroff, Alexander C., Giri, Jay et al. · 2021 · JAMA Network Open
68. SGLT2 Inhibitors and the Diabetic Kidney
    Paola Fioretto, Alberto Zambon, Marco Rossato, Luca Busetto, Roberto Vettor · 2016 · Diabetes Care
69. Tirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis
    Sattar, Naveed, McGuire, Darren K., Pavo, Imre, Weerakkody, Govinda J., Nishiyama, Hiroshi, Wiese, Russell J., Zoungas, Sophia · 2022 · Nature Medicine
70. Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective
    Wei Yu, Jidong Cheng · 2020 · Frontiers in Pharmacology
71. Japanese Clinical Practice Guideline for Diabetes 2019
    Eiichi Araki, Atsushi Goto, Tatsuya Kondo, Mitsuhiko Noda, Hiroshi Noto, Hideki Origasa, Haruhiko Osawa, Akihiko Taguchi, Yukio Tanizawa, Kazuyuki Tobe et al. · 2020 · Journal of Diabetes Investigation
72. Development of SGLT1 and SGLT2 inhibitors
    Rieg, Timo, Vallon, Volker · 2018 · Diabetologia
73. Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology
    Ele Ferrannini · 2017 · Cell Metabolism
74. Hyperglycemia Induces Trained Immunity in Macrophages and Their Precursors and Promotes Atherosclerosis
    Laurienne Edgar, Naveed Akbar, Adam T. Braithwaite, Thomas Krausgruber, Héctor Gallart-Ayala, Jade Bailey, Alastair Corbin, Tariq E. Khoyratty, Joshua T. Chai, Mohammad Alkhalil et al. · 2021 · Circulation
75. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
    American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., McCoy, Rozalina G., Aleppo, Grazia, Balapattabi, Kirthikaa, Beverly, Elizabeth A., Briggs Early, Kathaleen, Bruemmer, Dennis, Das, Sandeep R., Echouffo-Tcheugui, Justin B. et al. · 2025 · Diabetes Care
76. Heart failure drug treatment
    Patrick Rossignol, Adrian F. Hernandez, Scott David Solomon, Faiez M. Zannad · 2019 · The Lancet
77. Emerging role of SGLT-2 inhibitors for the treatment of obesity
    Pereira, Maria J., Eriksson, Jan W. · 2019 · Drugs
78. Mitochondria in acute myocardial infarction and cardioprotection
    Chrishan J. A. Ramachandra, Sauri Hernández‐Reséndiz, Gustavo E Crespo-Avilan, Ying‐Hsi Lin, Derek John Hausenloy · 2020 · EBioMedicine
79. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
    Milton Packer, Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, Faiez M. Zannad · 2017 · JAMA Cardiology
80. Cardiorenal Syndrome Revisited
    Faiez M. Zannad, Patrick Rossignol · 2018 · Circulation
81. Left ventricular hypertrophy and hypertension
    Mehmet Yildiz, Ahmet Afşin Oktay, Merrill H. Stewart, Richard V. Milani, Héctor O. Ventura, Carl J. Lavie · 2019 · Progress in Cardiovascular Diseases
82. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation
    Kolijn, Detmar, Pabel, Steffen, Tian, Yanna, Lódi, Mária, Herwig, Melissa, Carrizzo, Albino, Zhazykbayeva, Saltanat, Kovács, Árpád, Fülöp, Gábor Á, Falcão-Pires, Inês et al. · 2021 · Cardiovascular Research
83. Effects of sodium‐glucose co‐transporter 2 ( <scp>SGLT2</scp> ) inhibitors on serum uric acid level: <scp>A</scp> meta‐analysis of randomized controlled trials
    Zhao, Yumo, Xu, Lubin, Tian, Dongli, Xia, Peng, Zheng, Hua, Wang, Li, Chen, Limeng · 2018 · Diabetes, Obesity and Metabolism
84. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor
    Fralick, Michael, Schneeweiss, Sebastian, Patorno, Elisabetta · 2017 · New England Journal of Medicine
85. Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging
    Arnold C.T. Ng, Victoria Delgado, Barry A. Borlaug, Jeroen Joost Bax · 2020 · Nature Reviews Cardiology
86. Diabetic Nephropathy: Perspective on Novel Molecular Mechanisms
    Luigi Gnudi, Richard J. Coward, David Andrew Long · 2016 · Trends in Endocrinology and Metabolism
87. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis
    Toyama, Tadashi, Neuen, Brendon L., Jun, Min, Ohkuma, Toshiaki, Neal, Bruce, Jardine, Meg J., Heerspink, Hiddo L., Wong, Muh Geot, Ninomiya, Toshiharu, Wada, Takashi et al. · 2019 · Diabetes, Obesity and Metabolism
88. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
    Brendan M. Everett, Marc Yves Donath, Aruna D. Pradhan, Tom Y. Thuren, Prem S Pais, José Carlos Nicolau, Robert J. Glynn, Peter Libby, Paul M. Ridker · 2018 · Journal of the American College of Cardiology
89. Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial
    Athinarayanan, Shaminie J., Adams, Rebecca N., Hallberg, Sarah J., McKenzie, Amy L., Bhanpuri, Nasir H., Campbell, Wayne W., Volek, Jeff S., Phinney, Stephen D., McCarter, James P. · 2019 · Frontiers in Endocrinology
90. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema
    Stanley S. Schwartz, Solomon Epstein, Barbara E. Corkey, Struan F.A. Grant, James R. Gavin, Richard B. Aguilar · 2016 · Diabetes Care
91. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction
    Remo H.M. Furtado, Marc P. Bonaca, Itamar Raz, Thomas A. Zelniker, Ofri Mosenzon, Avivit Cahn, Julia Kuder, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter et al. · 2019 · Circulation
92. 8. Cardiovascular Disease and Risk Management
    American Diabetes Association · 2016 · Diabetes Care
93. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
    Scott David Solomon, Rudolf A. de Boer, David L. DeMets, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail Kosiborod, Carolyn S.P. Lam, Felipe A. Martínez, Sanjiv Jayendra Shah, Daniel P. Lindholm et al. · 2021 · European Journal of Heart Failure
94. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction
    Maddox, Thomas M., Januzzi, James L., Allen, Larry A., Breathett, Khadijah, Brouse, Sara, Butler, Javed, Davis, Leslie L., Fonarow, Gregg C., Ibrahim, Nasrien E., Lindenfeld, JoAnn et al. · 2024 · Journal of the American College of Cardiology
95. Sulfated modification of polysaccharides: Synthesis, characterization and bioactivities
    Zhijun Wang, Jianhua Xie, Mingyue Shen, Shaoping Nie, Mingyong Xie · 2018 · Trends in Food Science & Technology
96. Sodium–Glucose Co-Transporter 2 Inhibition with Empagliflozin Improves Cardiac Function in Non-Diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction
    Salva R. Yurista, Herman H.W. Silljé, Silke U. Oberdorf‐Maass, Elisabeth‐Maria Schouten, Mario Pávez, Jan‐Luuk Hillebrands, Harry van Goor, Dirk Jan van Veldhuisen, Rudolf A. de Boer, Berend Daan Westenbrink · 2019 · European Journal of Heart Failure
97. Japanese Clinical Practice Guideline for Diabetes 2016
    Masakazu Haneda, Mitsuhiko Noda, Hideki Origasa, Hiroshi Noto, Daisuke Yabe, Yukihiro Fujita, Atsushi Goto, Tatsuya Kondo, Eiichi Araki · 2018 · Diabetology International
98. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
    Piero Baglioni · 2019 · New England Journal of Medicine
99. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
    Ray, Kausik K, Colhoun, Helen M, Szarek, Michael, Baccara-Dinet, Marie, Bhatt, Deepak L, Bittner, Vera A, Budaj, Andrzej J, Diaz, Rafael, Goodman, Shaun G, Hanotin, Corinne et al. · 2019 · The Lancet Diabetes &amp; Endocrinology
100. Nighttime Blood Pressure Phenotype and Cardiovascular Prognosis: Practitioner-Based Nationwide JAMP Study
     Kario, Kazuomi, Hoshide, Satoshi, Mizuno, Hiroyuki, Kabutoya, Tomoyuki, Nishizawa, Masafumi, Yoshida, Tetsuro, Abe, Hideyasu, Katsuya, Tomohiro, Fujita, Yumiko, Okazaki, Osamu et al. · 2020 · Circulation